JUNTEN BIO

Based in Japan, JUNTEN BIO develops innovative cell therapeutics focused on achieving immune tolerance in organ transplantation, particularly through its flagship product, the induced regulatory T cell (JB-101). JUNTEN BIO, founded in 2018 in Tokyo, Japan, is engaged in developing cell therapies for organ transplantation. The company has secured funding, most recently raising JPY 200. 000 mn in November 2023 from Fujifilm Holdings Corporation.

Over its history, JUNTEN BIO has completed four deals, with its total capital raised reaching JPY 200. 000 mn. JUNTEN BIO specializes in the development of innovative cell therapeutics aimed at achieving immune tolerance in organ transplantation. Its flagship product, JB-101, is designed to suppress immune rejection responses in organ transplant patients, specifically for liver and kidney transplants.

Currently, the company is conducting clinical trials to validate JB-101’s efficacy, especially in living donor liver transplantation. JUNTEN BIO serves healthcare providers and institutions involved in transplant surgeries, with a geographic focus on Japan and plans to expand globally. JUNTEN BIO generates revenue through collaborations with healthcare institutions for clinical trials and potential commercialization of JB-101. Revenue streams include partnerships with hospitals and research institutions utilizing their products, licensing agreements with pharmaceutical companies, R&D service fees, milestone payments for regulatory approvals, and royalties on JB-101 sales following commercialization.

In November 2023, JUNTEN BIO raised JPY 200. 000 mn in venture funding from Mizuho Capital, aimed at revitalizing and sustaining growth in the Japanese economy. The company plans to expand its product line by enhancing JB-101 and exploring new therapeutic applications. Additionally, JUNTEN BIO is targeting international markets for its cell therapies, facilitating partnerships with medical centers globally.